FDA pembrolizumab coverage for business development, investment, and market access teams
Medicare price rule could hit Keytruda and Opdivo subcutaneous launches
FDA approves belzutifan plus pembrolizumab for adjuvant RCC
FDA priority review advances belzutifan plus pembrolizumab in adjuvant RCC
FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label
FDA approves Merck’s Keytruda for adjuvant NSCLC treatment
FDA approves Keytruda for adjuvant NSCLC, a Merck catalyst
FDA approves Keytruda adjuvant NSCLC use in early-stage lung cancer
FDA approves Keytruda adjuvant NSCLC use: what Merck investors should watch
Novo Nordisk CagriSema Phase 3 Obesity Results Signal Key Catalyst
5 Notable Oncology FDA Approvals Granted in May: A B2B Analysis
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
FDA Accelerated Approval Oncology: 2026 Review of Evolving Pathways